Role of oxidative stress in diabetes-mediated vascular dysfunction: Unifying hypothesis of diabetes revisited

Vascular Pharmacology

Volumn 57, Issue 5-6, 2012, Pages 139-149

  Schaffer, Stephen W ^a   Jong, Chian Ju ^a   Mozaffari, Mahmood ^b  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Diabetic complications; Glyceraldehyde 3 phosphate dehydrogenase inactivation by ribosylation; Oxidative stress; Vascular damage

Indexed keywords

1 PHOSPHOFRUCTOKINASE; GLYCERALDEHYDE 3 PHOSPHATE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; PYRUVATE KINASE; REACTIVE OXYGEN METABOLITE;

DIABETES MELLITUS; DIABETIC ANGIOPATHY; ENZYME INACTIVATION; ENZYME MECHANISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HYPOTHESIS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; ENDOTHELIAL CELLS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; GLYCOLYSIS; HUMANS; OXIDATIVE STRESS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 84865616201     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2012.03.005     Document Type: Review

References (155)

1. Aronson D., Rayfield E.J. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc. Diabetol. 2002, 1:1-10.
2. Balkau B., Shipley M., Jarrett R.J., Pyorala K., Pyorala M., Forhan A., Eschwege E. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. Diabetes Care 1998, 21:360-367.
3. Beisswenger P.J., Howell S.K., Smith K., Szwergold B.S. Glyceraldehyde-3-phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes. Biochim. Biophys. Acta 2003, 1637:98-106.
4. Bendall J.K., Alp N.J., Warrick N., Cai S., Adlam D., Rockett K., Yokoyama M., Kawashima S., Channon K.M. Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and eNOS coupling in vivo. Circ. Res. 2005, 97:864-871.
5. 2+ ATPase. Diabetes 2004, 53:463-473.
6. Blatnik M., Frizzell N., Thorpe S.R., Baynes J.W. Inactivation of glyceraldehydes-3-phosphate dehydrogenase by fumarate in diabetes: formation of S-(2-succinyl)cysteine, a novel chemical modification of protein and possible biomarker of mitochondrial stress. Diabetes 2008, 57:41-49.
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
8. Bucala R., Tracey K.J., Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest. 1991, 87:432-438.
9. Butler R., Morris A.D., Belch J.J.F., Hill A., Struthers A.D. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000, 35:746-751.
10. Cai L., Kang Y.J. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc. Toxicol. 2001, 1:181-193.
11. Campbell M., Anderson P., Trimble E.R. Glucose lowers the threshold for human aortic vascular smooth muscle cell migration: inhibition by protein phosphatase-2A. Diabetologia 2008, 51:1068-1080.
12. Cerella C., D'Alessio M., Cristofanon S., DeNicola M., Radogna F., Dicato M., Diederich M., Ghibelli L. Subapoptogenic oxidative stress strongly increases the activity of the glycolytic enzyme, glyceraldehyde-3-phosphate dehydrogenase. Ann. N. Y. Acad. Sci. 2009, 1171:583-590.
13. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causual" antioxidant therapy. Diabetes Care 2003, 26:1589-1596.
14. Cersosimo E., DeFronzo R.A. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab. Res. Rev. 2006, 22:423-436.
15. Chan N.N., Vallance P., Colhoun H.M. Nitric oxide and vascular responses in type 1 diabetes. Diabetologia 2000, 43:137-147.
16. Channon K.M. Tetrahydrobiopterin: regulator of endothelial nitric oxide synthase in vascular disease. Trends Cardiovasc. Med. 2004, 14:323-327.
17. Chen C.A., Wang T.Y., Varadharaj S., Reyes L.A., Hermann C., Talukder M.A., Chen Y.R., Druhan I.J., Zweier J.L. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 2010, 468:1115-1118.
18. Clark R.J., McDonough P.M., Swanson E., Trost S.U., Suzuki M., Fukuda M., Dillmann W.H. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J. Biol. Chem. 2003, 278:44230-44237.
19. 2-induced block of glycolysis as an active ADP-ribosylation reaction protecting cells from apoptosis. FASEB J. 2000, 14:2266-2276.
20. Connelly K.A., Kelly D.J., Zhang Y., Prior D.L., Advani A., Cox A.J., Thai K., Krum H., Gilbert R.E. Inhibition of protein kinase C-β by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ. Heart Fail. 2009, 2:129-137.
21. Cotter M.A., Jack A.M., Cameron N.E. Effects of protein kinase Cβ inhibitor LY333531on neural and vascular function in rats with streptozotocin-induced diabetes. Clin. Sci. 2002, 103:311-321.
22. Desco M.-C., Asensi M., Marquez R., Martinez-Valls J., Vento M., Pallardo F.V., Sastre J., Vina J. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 2002, 51:1118-1124.
23. deVegt F., Dekker J.M., Ruhe H.G., Stehouwer C.D.A., Nijpels G.B.L.M., Heine R.J. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999, 42:926-931.
24. Diatchuk V., Lotan O., Koshkin V., Wikstroem P., Pick E. Inhibition of NADPH oxidase activation by 4-(2-aminoethyl)-benzenesulfonyl fluoride and related compounds. J. Biol. Chem. 1997, 272:13292-13301.
25. DiLisa F., Kaludercic N., Carpi A., Menabo R., Giorgio M. Mitochondria and vascular pathology. Pharmacol. Rep. 2009, 61:123-130.
26. Ding H., Aljofan M., Triggle C.R. Oxidative stress and increased eNOS and NADPH oxidase expression in mouse microvessel endothelial cells. J. Cell. Physiol. 2007, 212:682-689.
27. Donahue R.P., Abbott R.D., Reed D.M., Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes 1987, 36:689-692.
28. Du X.-L., Edelstein D., Rossetti L., Fantus I.G., Goldberg H., Ziyadeh F., Wu J., Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12222-12226.
29. Du X., Matsumura T., Edelstein D., Rossetti L., Zsengeller Z., Szabo C., Brownlee M. Inhibition of GAPDH activity by poly (ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J. Clin. Invest. 2003, 112:1049-1057.
30. Du Y., Miller C.M., Kern T.S. Hyperglycemia increases mitochondrial superoxide in retinal and retinal cells. Free Radic. Biol. Med. 2003, 35:1491-1499.
31. Du X., Edelstein D., Obici S., Higham N., Zou M.-H., Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J. Clin. Invest. 2006, 116:1071-1080.
32. Elmi S., Sallam N.A., Rahman M.M., Teng X., Hunter A.L., Mojen-Afshari F., Khazaei M., Granville D.J., Laher I. Sulfaphenazole treatment restores endothelium-dependent vasodilation in diabetic mice. Vascul. Pharmacol. 2008, 48:1-8.
33. Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev. 2002, 23:599-622.
34. Evcimen N.D., King G.L. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol. Res. 2007, 55:498-510.
35. Farmer D.G.S., Kennedy S. RAGE, vascular tone and vascular disease. Pharmacol. Ther. 2009, 124:185-194.
36. Fatehi-Hassanabad Z., Chan C.B., Furman B.L. Reactive oxygen species and endothelial function in diabetes. Eur. J. Pharmacol. 2010, 636:8-17.
37. Fearon I.M., Faux S.P. Oxidative stress and cardiovascular disease: novel tools give (free) radical insight. J. Mol. Cell. Cardiol. 2009, 47:372-381.
38. Fisslthaler B., Michaelis U.R., Randriamboavonjy V., Busse R., Fleming I. Cytochrome p450 epoxygenases and vascular tone: novel role of HMG-CoA reductase inhibitors in the regulation of CYP2C expression. Biochim. Biophys. Acta 2003, 1619:332-339.
39. Fleming T., Cuny J., Nawroth G., Djuric Z., Humpert P.M., Zeier M., Bierhaus A., Nawroth P.P. Is diabetes an acquired disorder of reactive glycose metabolites and their intermediates?. Diabetologia 2012, 55:1151-1155.
40. Forstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch. - Eur. J. Physiol. 2010, 459:923-939.
41. Forstermann U., Sessa W.C. Nitric oxide synthases: regulation and fucntion. Eur. Heart J. 2012, 33:829-837.
42. Fortuna A., San Jose G., Moreno M.U., Diez J., Zalba G. Oxidative stress and vascular remodeling. Exp. Physiol. 2005, 90:457-462.
43. Gao L., Mann G.E. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc. Res. 2009, 82:9-20.
44. Ghahary A., Chakrabarti S., Sima A.A.F., Murphy L.J. Effect of insulin and Stat1 on aldose reductase expression in diabetic rats. Diabetes 1991, 40:1391-1396.
45. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ. Res. 2010, 107:1058-1070.
46. Giugliano D., Marfella R., Coppola L., Verrazzo G., Acampora R., Giunta R., Nappo F., Lucareeli C., D'Onofrio F. Vascular effects of acute hyperglycemia in humans are reversed by l-arginine: evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997, 95:1783-1790.
47. Gleissner C.A., Sander J.M., Nadler J., Ley K. Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1137-1143.
48. Grishko V., Pastukh V., Solodusko V., Gillespie M., Azuma J., Schaffer S. Apoptotic cascade initiated by angiotensin II in neonatal cardiomyocytes: role of DNA damage. Am. J. Physiol. 2003, 285/286:H2364-H2372.
49. Guzik T.J., West N., Pillai R., Taggart D., Channon K.M. Nitric oxide modulates superoxide release and peroxynitrite formation. Hypertension 2002, 39:1088-1094.
50. Haffner S.M., Letho S., Ronnamaa T., Pyorala K., Laakso M. Coronary heart disease mortality in subjects with type 2 diabetes and in non-diabetic subjects with and without previous myocardial infarction. N. Engl. J. Med. 1998, 339:229-234.
51. Hanefield M., Koehler C., Schaper F., Fuecker K., Henkel E., Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 1999, 144:229-235.
52. Hara M.R., Cascio M.B., Sawa A. GAPDH as a sensor of NO stress. Biochim. Biophys. Acta 2006, 1762:502-509.
53. Harja E., Bucciarelli L.G., Lu Y., Stern D.M., Zou Y.S., Schmidt A.M., Yan S.-F. Early growth response-1 promotes atherogenesis: mice deficient in early growth response-1 and apolipoprotein E display decrease atherosclerosis and vascular inflammation. Circ. Res. 2004, 94:333-339.
54. Harja E., Chang J.S., Lu Y., Leitges M., Zou Y.S., Schmidt A.M., Yan S.-F. Mice deficient in PKCβ and apolipoprotein E display decreased atherosclerosis. FASEB J. 2009, 23:1081-1091.
55. Hassinen I. Regulation of mitochondrial respiration in heart muscle. Mitochondria: The Dynamic Organelle 2007, 3-25. Springer Science and Business Media, LLC, New York. S.W. Schaffer, M.S. Suleiman (Eds.).
56. Horvath E.M., Benko R., Kiss L., Muranyi M., Pek T., Fekete K., Barany T., Somlai A., Csordas A., Szabo C. Rapid 'blycaemic swings' induce nitrosative stress, activate poly(ADP-ribose)polymerase and impair endothelial function in a rat model of diabetes. Diabetologia 2009, 52:952-961.
57. Inkster M.E., Cotter M.A., Cameron N.E. Treatment with the xanthine oxidase inhibitor, allopurinol, improves nerve and vascular function in diabetic rats. Eur. J. Pharmacol. 2007, 561:63-71.
58. Inoguchi T., Li P., Umeda F., Yu H.Y., Kakimoto M., Imamura M., Aoki T., Etoh T., Hashimoto T., Naruse M., Sano H., Utsumi H., Nawata H. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000, 49:1939-1945.
59. Ishii H., Jirousek M.R., Koya D., Takagi C., Xia P., Clermont A., Bursell S.E., Kern T.S., Ballas L.M., Heath W.F., Stamm L.E., Feener E.P., King G.L. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 1996, 272:728-731.
60. + cells. Invest. Ophthalmol. Vis. Sci. 2011, 52:5092-5104.
61. Jo J., Otani H., Jo F., Shimazu T., Okazaki T., Yoshioka K., Fujita M., Kosaki A., Iwasaka T. Inhibition of nitric oxide synthase uncoupling by sepiapterin improves left ventricular function in streptozotocin-induced diabetic mice. Clin. Exp. Pharmacol. Physiol. 2011, 38:485-493.
62. Kanwar M., Chan P.-S., Kern T.S., Kowluru R.A. Oxidative damage in the retinal mitochondria of diabetic mice: possible protection by superoxide dismutase. Invest. Ophthalmol. Vis. Sci. 2007, 48:3805-3811.
63. Kitada M., Koya D., Sugimoto T., Isono M., Araki S.-I., Kashiwaga A., Haneda M. Translocation of glomerular p47 phox and p67 phox by protein kinase C-β activation is required for oxidative stress in diabetic nephropathy. Diabetes 2003, 52:2603-2614.
64. Kowluru R.A., Atasi L., Ho Y.-S. Role of mitochondrial superoxide dismutase in the development of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2006, 47:1594-1599.
65. Kuboki K., Jiang Z.Y., Takahara N., Ha S.W., Igarashi M., Yamauchi T., Feener E.P., Herbert T.P., Rhodes C.J., King G.L. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000, 101:676-681.
66. Kusner L.L., Sarthy V.P., Mohr S. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase: a role in high glucose-induced apoptosis in retinal Muller cells. Invest. Ophthalmol. Vis. Sci. 2004, 45:1553-1561.
67. Lamharzi N., Renard C.B., Kramer F., Pennathur S., Heinecke J.W., Chait A., Bornfeldt K.E. Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions: potential role of glucose-oxidized LDL. Diabetes 2004, 53:3217-3225.
68. Lee H.S., Son S.M., Kim Y.K., Hong K.W., Kim C.D. NAD(P)H oxidase participates in the signaling events in high glucose-induced proliferation of vascular smooth muscle cells. Life Sci. 2003, 72:2719-2730.
69. phox subunit. J. Biol. Chem. 2003, 278:12094-12100.
70. Li J.-M., Shah A.M. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am. J. Physiol. 2004, 287:R1014-R1030.
71. phox in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-alpha. Circ. Res. 2002, 90:143-150.
72. Li N., Ragheb K., Lawler G., Sturgis J., Rajwa B., Melendez J.A., Robinson J.P. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J. Biol. Chem. 2003, 278:8516-8525.
73. Liu S., Ma X., Gong M., Shi L., Lincoln T., Wang S. Glucose down-regulation of cGMP-dependent protein kinase I expression in vascular smooth muscle cell involves NAD(P)H oxidase-derived reactive oxygen species. Free Radic. Biol. Med. 2007, 42:852-863.
74. Madsen-Bouterse S., Mohammad G., Kowluru R.A. Glyceraldehyde-3-phosphate dehydrogenase in retinal microvasculature: implications for the development and progression of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2010, 51:1765-1772.
75. Maiese K., Morhan S.D., Chong Z.Z. Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr. Neurovasc. Res. 2007, 4:63-71.
76. Mazzone T., Chait A., Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008, 371:1800-1809.
77. 2+ but requires phosphorylation by Akt at Ser 1179. J. Biol. Chem. 2001, 276:30392-30398.
78. Moore L.C., Thorup C., Ellinger A., Paccione J., Casellas D., Kaskel F.J. Advanced glycosylation end-products and NO-dependent vasodilation in renal afferent arterioles from diabetic rats. Acta Physiol. Scand. 2000, 168:101-106.
79. Mueller C.F., Laude K., McNally I.S., Harrison D.G. Redox mechanisms in blood vessels. Arterioscler. Thromb. Vasc. Biol. 2005, 2:274-278.
80. Muller G., Morawietz H. Nitric oxide, NAD(P)H oxidase, and atherosclerosis. Antioxid. Redox Signal. 2009, 11:1711-1731.
81. Munzel T., Daiber A., Ullrich V., Mulsch A. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1551-1557.
82. Nagareddy P.R., Xia Z., McNeill J.H., MacLeod K.M. Increased expression of iNOS is associated with endothelial dysfunction and impaired pressor responsiveness in streptozotocin-induced diabetes. Am. J. Physiol. 2005, 289:H2144-H2152.
83. Naoyuki K., Shin F., Toshikazu H., Tatsuo H., Kenjiro K., Toshitaka N., Takanori U., Tetsuya Y., Hisashi Y., Yuji M. Placebo-controlled, double-blind study of the non-purine selective xanthine oxidase inhibitor, Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J. Clin. Rheumatol. 2011, 17:S19-S26.
84. Nassar T., Kadery B., Lotan C., Da'as N., Kleinman Y., Haj-Yehia A. Effects of the superoxide dismutase-mimetic compound tempol on endothelial dysfunction in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 2002, 436:111-118.
85. Neely J.R., Rovetto M.J., Oram J.F. Myocardial utilization of carbohydrate and lipids. Prog. Cardiovasc. Dis. 1972, 15:289-328.
86. Newsholme P., Haber E.P., Hirabara S.M., Rebelato E.O., Procopio J., Morgan D., Oliveira-Emilio H.D., Carpinelli A.R., Curi R. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J. Physiol. 2007, 583:9-24.
87. Nishikawa T., Edelstein D., Du X.L., Yamagishi S.-I., Matsumura T., Kaneda Y., Yorek M.A., Beebe D., Oats P.J., Hammes H.-P., Giardino I., Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
88. Nishikawa T., Kukidome D., Sonoda K., Fujlisawa K., Matsuhisa T., Motoshima H., Matsumura T., Araki E. Impact of mitochondrial ROS production on diabetic vascular complications. Diabetes Res. Clin. Pract. 2007, 77S:S41-S45.
89. Pacher P., Szabo C. Role of poly (ADP-ribose) polymerase-1 activation in pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid. Redox Signal. 2005, 7:1568-1580.
90. Pacher P., Szabo C. Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr. Opin. Pharmacol. 2006, 6:136-141.
91. Pacher P., Liaudet L., Soriano F.G., Mabley J.G., Szabo E., Szabo C. The role of poly (ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 2002, 51:514-521.
92. Palmeira C.M., Rolo A.P., Berthlaume J., Bjork J.A., Wallace K.B. Hyperglycemia decreases mitochondrial function: The regulatory role of mitochondrial biogenesis. Toxicol. Appl. Pharmacol. 2007, 225:214-220.
93. Park C.R., Morgan H.E., Henderson M.J., Regen D.M., Cadenas E., Post R.L. Hormones and organic metabolism. Recent Prog. Horm. Res. 1961, 17:493-538.
94. Park W.H., Han Y.W., Kim S.H., Kim S.Z. An ROS generator, antimycin A, inhibits the growth of HeLa cells via apoptosis. J. Cell. Biochem. 2007, 102:98-109.
95. Pfeiffer S., Leopold E., Schmidt K., Brunner F., Mayer B. Inhibition of nitric oxide synthesis by NG-nitro-l-arginine methyl ester (l-NAME): requirement for bioactivation to the free acid, NG-nitro-l-arginine. Br. J. Pharmacol. 1996, 118:1433-1440.
96. Pieper G.M., Gross G.J. Oxygen free radicals abolish endothelium-dependent relaxation in diabetic rat aorta. Am. J. Physiol. 1988, 255:H825-H833.
97. Plutzky J. Inflammation in atherosclerosis and diabetes mellitus. Rev. Endocr. Metab. Disord. 2004, 5:255-259.
98. Quagliaro L., Piconi L., Assaloni R., Martinelli L., Motz E., Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells. Diabetes 2003, 52:2795-2804.
99. Quagliaro L., Piconi L., Assaloni R., Da Ros R., Maier A., Zuodar G., Ceriello A. Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis 2005, 183:259-267.
100. Quijano C., Castro L., Peluffo G., Valez V., Radi R. Enhanced mitochondrial superoxide in hyperglycemic endothelial cells: direct measurements and formation of hydrogen peroxide and peroxynitrite. Am. J. Physiol. 2007, 293:H3404-H3414.
101. Radi R., Cassina A., Hodara R., Quijano C., Castro L. Peroxynitrite reactions and formation in mitochondria. Free Radic. Biol. Med. 2002, 33:1451-1464.
102. Rajesh M., Mukhopadhyay P., Batkai S., Mukhopadhyay B., Patel V., Hasko G., Szabo C., Mabley J.G., Liaudet L., Pacher P. Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy. J. Cell. Mol. Med. 2009, 13:2330-2341.
103. Ramasamy R., Goldberg I.J. Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. Circ. Res. 2010, 106:1449-1458.
104. Randle P.J., Garland P.B., Hales C.N., Newsholme E.A., Denton R.M., Pogson C.I. Interactions of metabolism and the physiological role of insulin. Recent Prog. Horm. Res. 1966, 22:1-44.
105. Ray R., Shah A.M. NADPH oxidase and endothelial function. Clin. Sci. 2005, 109:217-226.
106. Rebrin I., Bregere C., Gallaher T.K., Sohal R.S. Detection of characterization of peroxynitrite-induced modifications of tyrosine, tryptophan, and methionine residues by tandem mass spectrometry. Methods Enzymol. 2008, 441:283-294.
107. Rey F.E., Cifuentes M.E., Kiarash A., Quinn M.T., Pagano P.J. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ. Res. 2001, 89:408-414.
108. Ricci C., Pastukh V., Leonard J., Turrens J., Wilson G., Schaffer D., Schaffer S.W. Mitochondrial DNA damage triggers mitochondrial superoxide generation and apoptosis. Am. J. Physiol. 2008, 294:C413-C422.
109. Roberts C.K., Barnard R.J., Sindhu R.K., Jurczak M., Ehdaie A., Vaziri N.D. Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome. Metab. Clin. Exp. 2006, 55:928-934.
110. Roe N.D., Thomas D.P., Ren J. Inhibition of NADPH oxidase alleviates experimental diabetes-induced myocardial contractile dysfunction. Diabetes Obes. Metab. 2011, 13:465-473.
111. Rojas A., Morales M.A. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. Life Sci. 2004, 76:715-730.
112. Rolo A.P., Palmeira C.M. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol. Appl. Pharmacol. 2006, 212:167-178.
113. Rosca M.G., Mustafa T.G., Kinter M.T., Ozdemir A.M., Kern T.S., Szweda L.I., Brownlee M., Monnier V.M., Weiss M.F. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am. J. Physiol. 2005, 289:F420-F430.
114. Satoh M., Fujimoto S., Haruna Y., Arakawa S., Horike H., Komai N., Sasaki T., Tsujioka K., Makino H., Kashihara N. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am. J. Physiol. 2005, 288:F1144-F1152.
115. Sen N., Hara M.R., Kornberg M.D., Cascio M.B., Bae B.-I., Shahani N., Thomas B., Dawson T.M., Dawson V.L., Snyder S.H., Sawa A. Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat. Cell Biol. 2008, 10:866-873.
116. Shankar R.R., Wu Y., Shen H.Q., Zhu J.S., Baron A.D. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 2000, 49:684-687.
117. Shao C.H., Capek H.L., Patel K.P., Wang M., Tang K., DeSouza C., Nagai R., Mayhan W., Periasamy M., Bidassee K.R. Carbonylation contributes to SERCA2a activity loss and diastolic dysfunction in a rat model of type 1 diabetes. Diabetes 2011, 60:947-959.
118. Shen G.X. Oxidative stress and diabetic cardiovascular disorders: roles of mitochondria and NADPH oxidase. Can. J. Physiol. Pharmacol. 2010, 88:241-248.
119. Sonta T., Inoguchi T., Tsubouchi H., Sekiguchi N., Kobayashi K., Matsumoto S., Utsumi H., Nawata H. Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity. Free Radic. Biol. Med. 2004, 37:115-123.
120. Soro-Paavonen A., Watson A.M.D., Li J., Paavonen K., Koitka A., Calkin A.C., Barit D., Coughlan M.T., Drew B.G., Lancaster G.I., Thomas M., Forbes J.M., Nawroth P.P., Bierhaus A., Cooper M.E., Jandeleit-Dahm K.A. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008, 57:2461-2469.
121. Srivastava S., Vladykovskaya E., Barski O.A., Spite M., Kaiserova K., Petrash J.M., Chung S.S., Hunt G., Dawn B., Bhatnagar A. Aldose reductase protects against early atherosclerotic lesion formation in apolipoprotein-E-null mice. Circ. Res. 2009, 105:793-802.
122. Stanley W.C., Lopaschuk G.D., McCormack J.G. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc. Res. 1997, 34:25-33.
123. Su J., Lucchesi P.A., Gonzalez-Villalobos R.A., Palen D.I., Rezk B.M., Suzuki Y., Boulares H.A., Matrougui K. Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1432-1438.
124. Suarez J., Scott B., Dillmann W.H. Conditional increase in SERCA2a protein is able to reverse contractile dysfunction and abnormal calcium flux in established diabetic cardiomyopathy. Am. J. Physiol. 2008, 295:R1439-R1445.
125. Sugihara K., Kitamura S., Yamada T., Ohta S., Yamashita K., Yasuda M., Fujii-Kuriyama Y. Aryl hydrocarbon receptor (AhR)-mediated induction of xanthine oxidase/xanthine dehydrogenase activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem. Biophys. Res. Commun. 2001, 281:1093-1099.
126. Szabo C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol. Lett. 2003, 140:105-112.
127. Szabo C. Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. Br. J. Pharmacol. 2009, 156:713-727.
128. Taegtmeyer H., McNulty P., Young M.E. Adaptation and maladaptation of the heart in diabetes: general concepts. Circulation 2002, 105:1727-1733.
129. Tang Y., Li G.D. Chronic exposure to high glucose impairs bradykinin-stimulated nitric oxide production by interfering with the phospholipase-C-implicated signaling pathway in endothelial cells: evidence for the involvement of protein kinase C. Diabetologia 2004, 47:2093-2104.
130. Tesfamariam B., Brown M.L., Cohen R.A. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J. Clin. Invest. 1991, 87:1643-1648.
131. Tesfamariam B., Brown M.L., Cohen R.A. Aldose reductase and myo-inositol in endothelial cell dysfunction caused by elevated glucose. J. Pharmacol. Exp. Ther. 1992, 263:153-157.
132. Topal G., Brunet A., Millanyoye E., Boucher J.L., Rendu F., Deyynck M.A., David-Dufilho M. Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobropterin. Free Radic. Biol. Med. 2004, 36:1532-1541.
133. Tsai S.-H., Hein T.W., Kuo L., Yang V.C. High glucose impairs EDHF-mediated dilation of coronary arterioles via reduced cytochrome P450 activity. Microvasc. Res. 2011, 82:356-363.
134. Turko I.V., Li L., Aulak K.S., Stuehr D.J., Chang J.-Y., Murad F. Protein tyrosine nitration in the mitochondria from diabetic mouse heart: implications to dysfunctional mitochondria in diabetes. J. Biol. Chem. 2003, 278:33972-33977.
135. Turrens J.F. Mitochondrial formation of reactive oxygen species. J. Physiol. 2003, 552:335-344.
136. Turrens J.F. Regulation of mitochondrial respiration in heart muscle. Mitochondria: The Dynamic Organelle 2007, 185-196. Springer Science and Business Media, LLC, New York. S.W. Schaffer, M.S. Suleiman (Eds.).
137. Turrens J.F., Alexandre A., Lehninger A.L. Ubisemiquinone in the electron donor for superoxide formation by complex III of heart mitochondria. Arch. Biochem. Biophys. 1985, 237:408-414.
138. Vanhoutte P.M., Shimokawa H., Tang E.H.C., Feletou M. Endothelial dysfunction and vascular disease. Acta Physiol. 2009, 196:193-222.
139. Vedantham S., Noh H., Ananthakrishnana R., Son N., Hallam K., Hu Y., Shen X., Rosario R., Lu Y., Ravindranath T., Drosatos K., Huggins L.A., Schmidt A.M., Goldberg I.J., Ramasamy R. Human aldose reductase expression accelerates atherosclerotic in diabetic apolipoprotein E-/- mice. Arterioscler. Thromb. Vasc. Biol. 2011, 8:1805-1813.
140. Vikramadithyan R.K., Hu Y., Noh H.-L., Laing C.-P., Hallam K., Tall A.R., Ramasamy R., Goldberg I.J. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J. Clin. Invest. 2005, 115:2434-2443.
141. Vincent M.A., Barrett E.J., Lindner J.R., Clark M.G., Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am. J. Physiol. 2003, 285:E123-E129.
142. Vlassara H., Fuh H., Makita Z., Krungkrai S., Cerami A., Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:12043-12047.
143. Wang Y., Peng F., Tong W., Sun H., Xu N., Liu S. The nitrate proteome in heart mitochondria of the db/db mouse model: characterization of nitrate tyrosine residues in SCOT. J. Proteome Res. 2010, 9:4254-4263.
144. Wautier M.P., Chappey O., Corda S., Stern D.M., Schmidt A.M., Wautier J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. 2001, 280:E685-E694.
145. phox homologues nox1 and nox4. Free Radic. Biol. Med. 2005, 39:381-391.
146. Wold L.E., Ceylan-Isik A.F., Ren J. Oxidative stress and stress signaling: menace of diabetic cardiomyopathy. Acta Pharmacol. Sin. 2005, 26:908-917.
147. Wu D., Cederbaum A.I. Combined effects of streptozotocin-induced diabetes plus 4-methylpyrazole treatment on rat liver cytochrome P4502E1. Arch. Biochem. Biophys. 1993, 302:175-182.
148. Xu S., He Y., Vokurkova M., Touyz R.M. Endothelial cells negatively modulate reactive oxygen species generation in vascular smooth muscle cells: role of thioredoxin. Hypertension 2009, 54:427-433.
149. Yan S.-F., Harja E., Andrassy M., Fujita T., Schmidt A.M. Protein kinase Cβ/early growth response-1 pathway: a key player in ischemia, atherosclerosis, and restenosis. J. Am. Coll. Cardiol. 2006, 48:A47-A55.
150. 2+ ATPase in diabetic aorta. Free Radic. Biol. Med. 2008, 45:756-762.
151. Yokoe S., Asahi M., Takeda T., Otsu K., Taniuchi N., Miyoshi E., Suzuki K. Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications for diabetic cardiomyopathy. Glycobiology 2010, 20:1217-1226.
152. Yoshinari K., Sato T., Okino N., Sugatani J., Miwa M. Expression and induction of cytochromes p450 in rat white adipose tissue. J. Pharmacol. Exp. Ther. 2004, 311:147-154.
153. Yu T., Robotham J.L., Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2653-2658.
154. Zhang D.X., Zou A.P., Li P.L. Ceramide-induced activation of NADPH oxidase and endothelial dysfunction in small coronary arteries. Am. J. Physiol. Heart Circ. Physiol. 2002, 284:H605-H612.
155. Zou M.H., Shi C., Cohen R.A. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J. Clin. Invest. 2002, 109:817-826.